Author:
Cammarata-Scalisi F,Capolino R,Magliozzi M,Novelli A,Galeotti A,Callea M
Reference15 articles.
1. Aubart M, Gazal S, Arnaud P, Benarroch L, Gross MS, Buratti J, et al. Association of modifiers and other genetic factors explain Marfan syndrome clinical variability. Eur J Hum Genet. 2018; 26(12): 1759-72.
2. Sandvik GF, Vanem TT, Rand-Hendriksen S, Cholidis S, Saethre M, Drolsum L. Ten-year reinvestigation of ocular manifestations in Marfan syndrome. Clin Exp Ophthalmol. 2019; 47(2): 212-8.
3. Handisides JC, Hollenbeck-Pringle D, Uzark K, Trachtenberg FL, Pemberton VL, Atz TW, et al. Health-related quality of life in children and young adults with Marfan syndrome. J Pediatr. 2019; 204: 250-255.e1.
4. Teixido-Tura G, Forteza A, Rodríguez-Palomares J, González Mirelis J, Gutiérrez L, Sánchez V, et al. Losartan versus Atenolol for prevention of aortic dilation in patients with Marfan syndrome. J Am Coll Cardiol. 2018; 72(14): 1613-8.
5. Isselbacher EM. Losartan for the treatment of Marfan syndrome: Hope Fades. J Am Coll Cardiol. 2018; 72(14): 1619-21.